Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Greysun is the Lead Guides Editor at GameRant, where he oversees game help coverage for everything from the biggest AAA releases to standout indie and live-service titles. Professionally, Greysun has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results